Report of the Cancer Therapy Evaluation Program Monitoring Plan for Secondary Acute Myeloid Leukemia Following Treatment With Epipodophyllotoxins
Mark Smith(National Institutes of Health), E. A. Gehan(The University of Texas MD Anderson Cancer Center), Richard S. Ungerleider(Unknown), Faheema Khan(King Saud University), Harold M. Maurer(University of Nebraska Medical Center), R Heyn(C. S. Mott Children's Hospital), Laure Cazenave(National Cancer Institute), Larry Rubinstein(National Cancer Institute)
Cited by 51
Related Papers
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914
How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials
|Journal of Clinical Oncology|2002|531
Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino)methanesulfon-m-anisidide and adriamycin
|Biochemistry|1981|375
Representation of older patients in cancer treatment trials
|Cancer|1994|349
Representation of African-Americans, Hispanics, and Whites in National Cancer Institute Cancer Treatment Trials
|JNCI Journal of the National Cancer Institute|1996|275